Drug Profile
Research programme: pain therapeutics - Nektar Therapeutics
Alternative Names: NKTR-174; NKTR-194; NKTR-195; NKTR-196; Sodium channel blockers - Nektar TherapeuticsLatest Information Update: 22 Feb 2023
Price :
$50
*
At a glance
- Originator Nektar Therapeutics
- Class Drug conjugates; Opioid analgesics; Small molecules
- Mechanism of Action NMDA receptor antagonists; Opioid kappa receptor agonists; Opioid mu receptor agonists; Opioid receptor agonists; Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute pain; Neuropathic pain; Visceral pain
Most Recent Events
- 22 Feb 2023 Discontinued - Preclinical for Acute pain in USA (PO)
- 22 Feb 2023 Discontinued - Preclinical for Neuropathic pain in USA (PO)
- 22 Feb 2023 Discontinued - Preclinical for Visceral pain in USA (PO)